REVIEW
|
doi:10.20944/preprints202210.0397.v1
Subject:
Public Health And Healthcare,
Health Policy And Services
Keywords:
biosimilars; regulatory process; animal studies; clinical efficacy testing; interchangeability; FDA; EMA; MHRA; MENA; cGMP
Online: 26 October 2022 (03:58:16 CEST)